Top

Published in:

01-11-2009 | Epidemiology

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers

Authors: Sharon Nofech-Mozes, Maureen Trudeau, Harriet K. Kahn, Rebecca Dent, Ellen Rawlinson, Ping Sun, Steven A. Narod, Wedad M. Hanna

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Abstract

Traditional prognostic markers for breast cancer include estrogen receptor (ER), progesterone receptor (ER) and HER2/neu. Negative staining for these three markers defines the ‘triple-negative’ phenotype. By adding markers for cytokeratin 5/6 and EGFR, triple-negative breast cancers can be divided into ‘basal-like’ and ‘normal-like’ subgroups. We conducted immuno-staining on a panel of 958 patients with breast cancer, using all five markers and we followed the patients for distal recurrence and death. We compared rates of distal recurrence in the basal-like and normal-like subgroups with that of women with ER-positive breast cancer. Only 16 of 958 women had normal-like breast cancers. These cancers resembled basal-like cancers in that they had a high proliferative index, but the women with normal-like breast cancers resembled ER-positive women in terms of distant recurrence. The addition of CK5/6 and EGFR to the standard panel (ER/PR/HER2/neu) defines a small subgroup of women with normal-like breast cancer. The prognosis of these women may be superior to that of basal-like breast cancers but firm conclusions cannot be made.

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. doi:10.1038/35021093 CrossRefPubMed

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423. doi:10.1073/pnas.0932692100 CrossRefPubMed

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.1073/pnas.191367098 CrossRefPubMed

van’ V, Dai H, Van d V et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. doi:10.1038/415530a CrossRef

Van d V, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. doi:10.1056/NEJMoa021967 CrossRef

Fadare O, Tavassoli FA (2007) The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol 14(5):358–373. doi:10.1097/PAP.0b013e31814b26fe CrossRefPubMed

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-0220 CrossRefPubMed

Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol 18(7):1133–1144. doi:10.1093/annonc/mdm271 CrossRefPubMed

Domagala W, Lasota J, Dukowicz A et al (1990) Vimentin expression appears to be associated with poor prognosis in node negative ductal NOS breast carcinomas. Am J Pathol 137:1299–1304PubMed

10.

Li H, Cherukuri P, Li N, Cowling V et al (2007) Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 67(2):501–510. doi:10.1158/0008-5472.CAN-05-4571 CrossRefPubMed

11.

Rakha EA, Putti TC, bd El-Rehim DM et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495–506. doi:10.1002/path.1916 CrossRefPubMed

12.

Hoadley KA, Weigman VJ, Fan C et al (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8:258. doi:10.1186/1471-2164-8-258 CrossRefPubMed

13.

van de RM, Perou CM, Tibshirani R et al (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161(6):1991–1996

14.

Rakha EA, El-Rehim DA, Paish C et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149–3156. doi:10.1016/j.ejca.2006.08.015 CrossRefPubMed

15.

Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13((15 Pt 1)):4429–4434. doi:10.1158/1078-0432.CCR-06-3045 CrossRefPubMed

16.

Gaedcke J, Traub F, Milde S et al (2007) Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 20(8):864–870. doi:10.1038/modpathol.3800830 CrossRefPubMed

17.

Palmieri D, Smith QR, Lockman PR et al (2006) Brain metastases of breast cancer. Breast Dis 26:139–147PubMed

18.

Dent R, Hanna WM, Ttrudeau M, et al. (2008) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat (in press)

19.

Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264–271. doi:10.1038/modpathol.3800528 CrossRefPubMed

20.

Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to pre-operative chemotherapy. Clin Cancer Res 11:5678–5685CrossRefPubMed

21.

Jumppanen M, Gruvberger-Saal S, Kauraniemi P et al (2007) Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9(1):R16. doi:10.1186/bcr1649 CrossRefPubMed

22.

Kreike B, van Kouwenhove M, Horlings H, et al. (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9(5):R65CrossRefPubMed

Title: Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
Authors: Sharon Nofech-Mozes
Maureen Trudeau
Harriet K. Kahn
Rebecca Dent
Ellen Rawlinson
Ping Sun
Steven A. Narod
Wedad M. Hanna
Publication date: 01-11-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0295-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Expression profile of microRNAs in c-Myc induced mouse mammary tumors

Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast

A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer

Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy

Risk factors for breast cancer from benign breast disease in a diverse population

Differentiation of benign and malignant breast lesions by mechanical imaging

Keynote webinar | Spotlight on antibody–drug conjugates in cancer